Acalabrutinib (Synonyms: 阿可替尼; ACP-196)
目录号: PL04750 纯度: ≥99%
CAS No. :1420477-60-6
商品编号 规格 价格 会员价 是否有货 数量
PL04750-5mg 5mg ¥618.18 请登录
PL04750-10mg 10mg ¥989.09 请登录
PL04750-50mg 50mg ¥3090.91 请登录
PL04750-100mg 100mg ¥4636.36 请登录
PL04750-200mg 200mg ¥6923.64 请登录
PL04750-500mg 500mg 询价 询价
PL04750-1g 1g 询价 询价
PL04750-10mM*1mLinDMSO 10mM*1mLinDMSO ¥680.00 请登录
Medlife所售产品仅用于科学研究(非临床研究),非药品不可食用,不可用于人体或动物的临床诊断和治疗,我们不为个人提供产品及服务。产品COA等资料,可至下方“质量控制”中下载。
中文名称
Acalabrutinib
中文别名
阿可替尼
英文名称
Acalabrutinib
英文别名
Acalabrutinib;Calquence;I42748ELQW;Benzamide, 4-(8-amino-3-((2S)-1-(1-oxo-2-butyn-1-yl)-2-pyrrolidinyl)imidazo(1,5-a)pyrazin-1-yl)-N-2-pyridinyl-;Acalabrutinib [INN];Acalabrutinib [USAN:INN];Calquence (TN);Benzamide, 4-[8-amino-3-[(2S)-1-(1-oxo-2-butyn-1-yl)-2-pyrrolidinyl]imidazo[1,5-a]pyrazin-1-yl]-N-2-pyridinyl-;Acalabrutinib(ACP196);GTPL8912;Acalabrutinib (JAN/USAN/INN);EX;Acalabrutinib(ACP-196)
Cas No.
1420477-60-6
分子式
C26H23N7O2
分子量
465.51
包装储存
Powder -20°C 3 years;4°C 2 years
产品详情
Acalabrutinib (ACP-196) 是一种具有口服活性,不可逆的,高度选择性的第二代 BTK 抑制剂。Acalabrutinib 与 BTK 的 ATP 结合口袋中的 Cys481 共价结合。Acalabrutinib 在慢性淋巴细胞性白血病 (CLL) 小鼠模型中显示出强大的靶向作用和功效。
生物活性
Acalabrutinib (ACP-196) is an orally active, irreversible, and highly selective second-generation BTK inhibitor. Acalabrutinib binds covalently to Cys481 in the ATP-binding pocket of BTK. Acalabrutinib demonstrates potent on-target effects and efficacy in mouse models of chronic lymphocytic leukemia (CLL).
性状
Solid
IC50 & Target[1][2]
IC50: 3 nM (BTK in CD69 B cell)
体外研究(In Vitro)
Acalabrutinib (ACP-196) inhibits tyrosine phosphorylation of downstream targets of ERK, IKB, and AKT, in the in vitro signaling assay on primary human CLL cells. In the human CLL NSG xenograft model, Acalabrutinib demonstrates on-target effects including decreased phosphorylation of PLCγ2, ERK and significant inhibition of CLL cell proliferation.
Acalabrutinib inhibits purified BTK with an IC50 of 3 nM and an EC50 of 8 nM in a human whole-blood CD69 B cell activation assay. Acalabrutinib has improved target specificity over ibrutinib with 323-, 94-, 19-, and 9-fold selectivity over the other TEC kinase family members (ITK, TXK, BMX, and TEC , respectively) and no activity against EGFR.
has not independently confirmed the accuracy of these methods. They are for reference only.
体内研究(In Vivo)
Acalabrutinib (100 mg twice per day) assessed for thrombus formation at injured arterioles of the mice, exhibits more selective for inhibiting BTK and has virtually no inhibition of platelet activity. has not independently confirmed the accuracy of these methods. They are for reference only.
运输条件
Room temperature in continental US; may vary elsewhere.
储存方式
Powder -20°C 3 years;4°C 2 years
ClinicalTrial
参考文献
[1]. Wu J, et al. Acalabrutinib (ACP-196): a selective second-generation BTK inhibitor. J Hematol Oncol. 2016 Mar 9;9:21
[2]. Herman SE, et al. The Brutons tyrosine kinase (BTK) inhibitor acalabrutinib demonstrates potent on-target effects and efficacy in two mouse models of chronic lymphocytic leukemia. Clin Cancer Res. 2016 Nov 30
溶解度数据
In Vitro: DMSO : 250 mg/mL (537.05 mM; Need ultrasonic)配制储备液
搜索质检报告(COA)

1:一般建议:溶解度为Medlife测试数据,可能与文献描述存在差异。这是由于生产工艺和批次不同产生的正常现象。为了使其更好的溶解,请用37℃加热试管并在超声波水浴中震动片刻。不同批次产品溶解度各有差异,仅做参考,具体以实验方案为准。

2:储存条件:粉末-20°C一般情况可以保存3年,溶于溶剂-80°C一般情况可以保存1年。不同产品及不同批次产品可能存在差异,请细致阅读产品信息,并辅助参考相关文献描述。

The molarity calculator equation
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
The dilution calculator equation
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2